Lai K N, Li P K, Lui S F, Au T C, Tam J S, Tong K L, Lai F M
Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin.
N Engl J Med. 1991 May 23;324(21):1457-63. doi: 10.1056/NEJM199105233242103.
The natural course of adult hepatitis B virus (HBV)-related membranous nephropathy in areas where HBV infection is endemic (characterized by vertical and horizontal transmission of HBV in early childhood) has not been fully defined.
We evaluated the clinical features, pathological findings, serologic profiles, therapeutic responses, and prognoses of 21 patients with adult-onset HBV-related membranous nephropathy. The patients were followed for a mean of 60 months (range, 12 to 108). Only patients with evidence of glomerular capillary deposition of hepatitis B e antigen (HBeAg) in a renal-biopsy specimen were included.
The clinical features and serologic studies suggested that the patients had acquired chronic HBV infection in early childhood; moreover, other causes of membranous nephropathy had been excluded. All were seropositive for hepatitis B surface antigen and had high titers of antibody to hepatitis B core antigen at first clinical presentation. HBeAg was detected in the serum of 17 patients (81 percent), yet only 3 had even slightly increased plasma alanine aminotransferase levels. The clinical response to therapy with interferon alfa was disappointing; only one of the five patients treated had a complete remission with seroconversion to antibody to HBeAg. Contrary to reports of studies in children, spontaneous remission of the nephrotic syndrome or proteinuria was uncommon in the adults with HBV-related membranous nephropathy whom we studied. Proteinuria and HBV antigenemia persisted in untreated patients. During the follow-up period, 29 percent of the patients had progressive renal failure and 10 percent required maintenance dialysis therapy.
The course of HBV-related membranous nephropathy in adults in areas where HBV is endemic is not benign. Regardless of treatment, the disease has a slowly but relentlessly progressive clinical course in approximately one third of patients.
在乙型肝炎病毒(HBV)感染流行地区(其特征为HBV在儿童早期通过垂直和水平传播),成人HBV相关膜性肾病的自然病程尚未完全明确。
我们评估了21例成人起病的HBV相关膜性肾病患者的临床特征、病理表现、血清学特征、治疗反应及预后。患者平均随访60个月(范围12至108个月)。仅纳入肾活检标本中有乙型肝炎e抗原(HBeAg)肾小球毛细血管沉积证据的患者。
临床特征和血清学研究提示患者在儿童早期获得慢性HBV感染;此外,已排除其他膜性肾病病因。所有患者首次临床表现时乙肝表面抗原均为血清学阳性,且乙肝核心抗原抗体滴度高。17例患者(81%)血清中检测到HBeAg,但仅3例血浆丙氨酸氨基转移酶水平略有升高。干扰素α治疗的临床反应令人失望;接受治疗的5例患者中仅1例完全缓解并血清转换为抗HBeAg抗体。与儿童研究报告相反,我们研究的成人HBV相关膜性肾病患者中,肾病综合征或蛋白尿自发缓解并不常见。未治疗患者蛋白尿和HBV抗原血症持续存在。随访期间,29%的患者出现进行性肾衰竭,10%的患者需要维持性透析治疗。
在HBV流行地区,成人HBV相关膜性肾病的病程并非良性。无论治疗与否,约三分之一的患者疾病呈缓慢但持续进展的临床病程。